Taken together, our first pan-cancer study indicated that SHC1 expression was correlated with clinical outcomes, genetic mutation, TMB, MSI, DNA methylation, RNA methylation, protein phosphorylation, immune cell infiltration, and tumor-associated macrophage. This evidence concerns the gene SHC1 and neoplasm.